Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-associated mortality worldwide with an overall five-year survival rate less than 7%. Accumulating evidence has revealed the cancer preventive and therapeutic effects of metformin, one of the most widely prescri...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Mol Cancer
Hlavní autoři: Chen, Ke, Qian, Weikun, Jiang, Zhengdong, Cheng, Liang, Li, Jie, Sun, Liankang, Zhou, Cancan, Gao, Luping, Lei, Meng, Yan, Bin, Cao, Junyu, Duan, Wanxing, Ma, Qingyong
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2017
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5525317/
https://ncbi.nlm.nih.gov/pubmed/28738823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-017-0701-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky